{"id":"W3088392406","doi":"10.1016/j.annonc.2020.08.451","title":"349TiP EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nab-PTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Genentech; Ipsen; Daiichi Sankyo Europe; Servier; European Society for Medical Oncology; Chugai Pharmaceutical; Vifor Pharma; Oncolytics Biotech; Novo Nordisk; Astellas Pharma; Eisai; Seagen; Daiichi-Sankyo; MacroGenics; Japan Surgical Society; Puma Biotechnology; Pfizer; Incyte; Menarini Silicon Biosystems; Mylan; Clovis Oncology; Teva Pharmaceutical Industries; Sanofi; Foundation Medicine; Genomic Health; GlaxoSmithKline; Amgen; Novartis Pharmaceuticals Corporation; G1 Therapeutics; Jounce Therapeutics; Celgene; AstraZeneca; ImmunoMedics; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Triple-negative breast cancer; PTEN; Internal medicine; Oncology; Breast cancer; Population; Fulvestrant; Cancer; Cancer research; PI3K/AKT/mTOR pathway; Tamoxifen","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001059191,0.001937429,0.002878395,0.0005569386,0.0003854348,0.0009363493,0.001079725,0.001722854,0.009011068],"category_scores_gemma":[0.0008994464,0.0007495846,0.001131095,0.0005002081,0.001129728,0.0009877943,0.0003478399,0.003293297,0.001814615],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005155909,"about_ca_system_score_gemma":0.001160275,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001141242,"about_ca_topic_score_gemma":0.002115634,"domain_scores_codex":[0.9996526,0.0001502334,0.00001994125,0.00007258166,0.00002420613,0.00008043632],"domain_scores_gemma":[0.999638,0.00008237261,0.00005173431,0.00002847131,0.00002376917,0.0001757651],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9691818,0.006577685,0.00021901,0.0006194005,0.0004810449,0.00002805703,0.00002497451,0.0002409351,0.006672857,0.0001098925,0.0007994183,0.01504483],"study_design_scores_gemma":[0.9454346,0.05197677,0.0007996347,0.00001770752,0.0002308705,0.00002392686,0.00001180714,0.000240684,0.0006160825,0.00007629873,0.0005607394,0.00001090692],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.977715,0.006079852,0.001794764,0.0008831191,0.0007739419,0.0053814,0.002410646,0.000652187,0.004309119],"genre_scores_gemma":[0.9763441,0.004635792,0.002431622,0.001710362,0.0004140461,0.005237161,0.002314544,0.0001086924,0.006803737],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009011068,"threshold_uncertainty_score":0.03014499,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07964210492149927,"score_gpt":0.4290398262502009,"score_spread":0.3493977213287016,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}